News
The collaboration will establish a secure AI-enabled platform to help Cedars-Sinai investigators analyze de-identified, multimodal clinical data from over 5 million patients.
Making Headlines in Healthcare Innovation






















































nference in the News
November 20, 2026
The collaboration will establish a secure AI-enabled platform to help Cedars-Sinai investigators analyze de-identified, multimodal clinical data from over 5 million patients.

November 18, 2026
Collaboration combines clinical trial and real-world insights to increase understanding of cardiometabolic disease

September 16, 2026
nference has been selected as one of TIME’s World’s Top HealthTech Companies of 2026, marking its second consecutive year on the list.
September 15, 2026
Reuters highlights nference’s analysis of clinical notes documenting BPC-157 use in 1,039 patients, amid limited evidence of the peptide’s safety and effectiveness.

September 2, 2026
Partnership will create a real-time, secure, Rush-hosted platform that makes de-identified, multimodal clinical data research-ready to accelerate discovery and improve patient care.

July 17, 2026
nference study suggest that some people can keep the weight off.

June 9, 2026
nference announced a series of publications from the Metabolic Agentic Intelligence Atlas initiative, or MAIA, a federated AI program that enables real-time synthesis of biomedical knowledge from the de-identified care patterns of over 30 million patients. The studies provide collectively, for the first-time, a high-resolution precision map of the impact of GLP-1, GIP, and other incretin therapies on the whole human body beyond weight-loss and glucose measurements that have been the primary endpoints of clinical studies thus far.

April 17, 2026
While Eli Lilly’s tirzepatide helps patients drop more weight than Novo Nordisk’s semaglutide, this might come with greater loss in lean body mass, according to …

of 10